Vis enkel innførsel

dc.contributor.authorMassey, Richard J
dc.contributor.authorDiep, Phoi Phoi
dc.contributor.authorRuud, Ellen
dc.contributor.authorBurman, Marta Maria
dc.contributor.authorKvaslerud, Anette Borger
dc.contributor.authorBrinch, Lorentz
dc.contributor.authorAakhus, Svend
dc.contributor.authorGullestad, Lars
dc.contributor.authorBeitnes, Jan Otto
dc.date.accessioned2021-01-22T08:26:34Z
dc.date.available2021-01-22T08:26:34Z
dc.date.created2021-01-11T21:05:01Z
dc.date.issued2020
dc.identifier.citationJournal of the American College of Cardiology. 2020, 2 (3), 460-471.en_US
dc.identifier.issn0735-1097
dc.identifier.urihttps://hdl.handle.net/11250/2724215
dc.description.abstractBackground Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a potentially curative therapy for malignant and nonmalignant diseases, is being increasingly used in younger patients. Although allo-HSCT survivors have an established increased risk of cardiovascular disease, there is limited knowledge of the long-term effects on cardiac function in survivors. Objectives The purpose of this study was to describe left ventricular (LV) systolic function in long-term allo-HSCT survivors treated in childhood, adolescence, or early adulthood. Methods Our cross-sectional cohort study included 104 patients (56% women), age 18 ± 10 years at time allo-HSCT with 17 ± 6 years of follow-up. Echocardiography included 2-dimensional (2D) and 3-dimensional (3D) analyses and speckle tracking imaging. In total, 55 healthy control subjects with a similar age, sex, and body mass index were used for comparison. Left ventricular systolic dysfunction (LVSD) was defined as reduced 2D left ventricular ejection fraction (LVEF) of <52% in men and <54% in women, and/or a reduced global longitudinal strain (GLS) of ≥−17%. Multivariable linear regression was used to determine independent predictors of 2D-LVEF and GLS. Results Allo-HSCT survivors had significantly reduced LV systolic function compared with control subjects: 2D-LVEF (55.2 ± 5.8% vs. 59.0 ± 2.9%; p < 0.001), 3D LVEF (54.0 ± 5.1% vs. 57.6 ± 2.7%; p < 0.001), and GLS (−17.5 ± 2.2% vs. −19.8 ± 1.4%; p < 0.001). LVSD was found in 44.2%, of whom 28.3% were symptomatic. Clinical factors independently associated with 2D-LVEF and/or GLS included age, anthracyclines, graft versus host disease (GVHD), heart rate, and hypertension. In the 45% of survivors pre-treated with anthracyclines, the effect of anthracyclines on 2D-LVEF and GLS was dose-dependent. Conclusions LVSD is common in long-term survivors of allo-HSCT treated in their youth. Pre-HSCT therapies with anthracyclines, age, heart rate, hypertension, and graft versus host disease are associated with measures of LV function.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleLeft Ventricular Systolic Function in Long-Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantationen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber460-471en_US
dc.source.volume2en_US
dc.source.journalJournal of the American College of Cardiologyen_US
dc.source.issue3en_US
dc.identifier.doi10.1016/j.jaccao.2020.06.011
dc.identifier.cristin1869420
dc.description.localcode© 2020 The authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the cc by-nc-nd license (http://creativecommns.org/licenses/by-nc-nd/4.0/).en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal